/ /

CLINICAL

Pearls from BCLA 2017: CLIDE and blepharitis
Pearls from BCLA 2017: CLIDE and blepharitisThe British Contact Lens Association (BCLA) celebrated its 40th birthday June 9-11 at its 2017 clinical conference and exhibition in Liverpool, UK. Optometry Times was there to hear the latest and live tweet from the meeting.
Selective techniques revolutionize treatment for retinoblastomaAdvancements in retinoblastoma have occurred in the areas of treatment, genetic testing, and diagnostic imaging.
Targeted vitreoretinal lymphoma therapies mimic other approaches
Targeted vitreoretinal lymphoma therapies mimic other approachesVitreoretinal lymphomas are both deceptive and deadly. While there are only about 350 cases reported annually in the United States, median survival is less than 5 years, said Rajesh C. Rao, MD.
Tapping gene therapy potential for inherited retinal diseases
Tapping gene therapy potential for inherited retinal diseasesThe gene therapy technology already exists to treat most inherited retinal disease. The current challenge is to drive down the costs of implementing the technology.
POAG: Enigmatic group of heterogenous diseases?Various subtypes of primary open-angle glaucoma might exist. Continued research is needed to identify the characteristics of each subtype for better management.
FDA approves tocilizumab, first therapy for GCA
FDA approves tocilizumab, first therapy for GCAThe FDA recently granted regulatory approval for tocilizumab (Actemra, Genentech), the first approved therapy for the treatment of adults with giant cell arteritis.
Pros and cons of compounded pharmaceuticalsCompounded pharmaceuticals have been used for decades, but does that mean they are reliable and safe? “Absolutely,” asserted Dante Pieramici, MD. “The literature disagrees,” said Julia Haller, MD.
New and different therapies emerging through uveitis pipelineLocal therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.
Endoillumination growth amplifies tissue visualizationEndoillumination for vitreoretinal surgery continues to improve with the introduction of brighter, safer light sources with color filters that may allow opportunities for better tissue visualization.
New concepts in diagnosis and treatmentIn the past decade, several significant advancements have been made in the arena of glaucoma diagnosis. Spectral domain optical coherence tomography (SD-OCT), newer algorithms in trend analysis of visual field studies, and combined visually evoked potential (VEP) and pattern electroretinography (ERG) studies have been the hallmarks of such recent advancements.